References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. Erratum in: CA Cancer J Clin 2020;70:313. https://doi.org/10.3322/caac.21492
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. https://doi.org/10.3322/caac.21442
- Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014;371:2140-2141. https://doi.org/10.1056/NEJMc1412266
- Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling pancreatic cancer with organoids. Trends Cancer 2016;2:176-190. https://doi.org/10.1016/j.trecan.2016.03.004
- Moreira L, Bakir B, Chatterji P, Dantes Z, Reichert M, Rustgi AK. Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer. Cell Mol Gastroenterol Hepatol 2017;5:289-298. https://doi.org/10.1016/j.jcmgh.2017.12.004
- Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer 2018;18:407-418. https://doi.org/10.1038/s41568-018-0007-6
- Maeng JE, Seo HY, Kim SC, Ku JL. Novel drug screening platform: tumor organoid. Korean J Pancreas Biliary Tract 2021;26:233-240. https://doi.org/10.15279/kpba.2021.26.4.233
- Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019;364:952-955. https://doi.org/10.1126/science.aaw6985
- Broutier L, Andersson-Rolf A, Hindley CJ, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc 2016;11:1724-1743. https://doi.org/10.1038/nprot.2016.097
- Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015;160:324-338. https://doi.org/10.1016/j.cell.2014.12.021
- Tiriac H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov 2018;8:1112-1129. https://doi.org/10.1158/2159-8290.CD-18-0349
- Tiriac H, Bucobo JC, Tzimas D, et al. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 2018;87:1474-1480. https://doi.org/10.1016/j.gie.2017.12.032
- Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S A 2019;116:26580-26590. https://doi.org/10.1073/pnas.1911273116
- Tiriac H, Plenker D, Baker LA, Tuveson DA. Organoid models for translational pancreatic cancer research. Curr Opin Genet Dev 2019;54:7-11. https://doi.org/10.1016/j.gde.2019.02.003
- Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
- Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-450. https://doi.org/10.1016/s1535-6108(03)00309-x
- Greggio C, De Franceschi F, Figueiredo-Larsen M, et al. Artificial three-dimensional niches deconstruct pancreas development in vitro. Development 2013;140:4452-4462. https://doi.org/10.1242/dev.096628
- Huch M, Bonfanti P, Boj SF, et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J 2013;32:2708-2721. https://doi.org/10.1038/emboj.2013.204
- Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med 2015;21:1364-1371. https://doi.org/10.1038/nm.3973
- Ootani A, Li X, Sangiorgi E, et al. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat Med 2009;15:701-706. https://doi.org/10.1038/nm.1951
- Clevers H. Modeling development and disease with organoids. Cell 2016;165:1586-1597. https://doi.org/10.1016/j.cell.2016.05.082
- Ohlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 2017;214:579-596. https://doi.org/10.1084/jem.20162024
- Biffi G, Oni TE, Spielman B, et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov 2019;9:282-301. https://doi.org/10.1158/2159-8290.CD-18-0710
- Sahin IH, Askan G, Hu ZI, O'Reilly EM. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? Ann Oncol 2017;28:2950-2961. https://doi.org/10.1093/annonc/mdx503
- Kim SC, Park JW, Seo HY, et al. Multifocal organoid capturing of colon cancer reveals pervasive intratumoral heterogenous drug responses. Adv Sci (Weinh) 2022;9:e2103360. https://doi.org/10.1002/advs.202103360
- Jeong N, Kim SC, Park JW, et al. Multifocal organoids reveal clonal associations between synchronous intestinal tumors with pervasive heterogeneous drug responses. NPJ Genom Med 2022;7:42. https://doi.org/10.1038/s41525-022-00313-0
- Song MH, Park JW, Kim MJ, et al. Colon cancer organoids using monoclonal organoids established in four different lesions of one cancer patient reveal tumor heterogeneity and different real-time responsiveness to anticancer drugs. Biomed Pharmacother 2022;152:113260. https://doi.org/10.1016/j.biopha.2022.113260
- Boj SF, Hwang CI, Baker LA, Engle DD, Tuveson DA, Clevers H. Model organoids provide new research opportunities for ductal pancreatic cancer. Mol Cell Oncol 2015;3:e1014757. https://doi.org/10.1080/23723556.2015.1014757
- Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009;4:1670-1680. https://doi.org/10.1038/nprot.2009.171
- Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014;159:176-187. https://doi.org/10.1016/j.cell.2014.08.016
- Walsh AJ, Cook RS, Skala MC. Functional optical imaging of primary human tumor organoids: development of a personalized drug screen. J Nucl Med 2017;58:1367-1372. https://doi.org/10.2967/jnumed.117.192534
- Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607. Erratum in: Nature 2012;492:290. Erratum in: Nature 2019;565:E5-E6. https://doi.org/10.1038/nature11003
- Caponigro G, Sellers WR. Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov 2011;10:179-187. https://doi.org/10.1038/nrd3385
- Hou S, Tiriac H, Sridharan BP, et al. Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening. SLAS Discov 2018;23:574-584. https://doi.org/10.1177/2472555218766842
- van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015;161:933-945. https://doi.org/10.1016/j.cell.2015.03.053
- Gleeson FC, Kipp BR, Kerr SE, et al. Characterization of endoscopic ultrasound fine-needle aspiration cytology by targeted next-generation sequencing and theranostic potential. Clin Gastroenterol Hepatol 2015;13:37-41. https://doi.org/10.1016/j.cgh.2014.10.017
- Zutter MM, Bloom KJ, Cheng L, et al. The cancer genomics resource list 2014. Arch Pathol Lab Med 2015;139:989-1008. https://doi.org/10.5858/arpa.2014-0330-CP